February 26, 2026

AHA Issues Pediatric Hypertriglyceridemia Statement

The scientific statement defines pancreatitis and atherosclerotic cardiovascular disease risk thresholds and outlines causes and management in youths.

Conexiant

February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 12, 2026

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Conexiant

February 12, 2026

Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

Conexiant

February 11, 2026

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Conexiant

February 09, 2026

Managing Idiopathic Acute Pancreatitis

Expert panel weighs evidence for genetic testing, cholecystectomy, and ERCP in patients with unexplained acute pancreatitis amid limited guideline direction.

Conexiant

February 04, 2026

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

KFF Health News

January 27, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Conexiant